Crystal Structures of Human Rip2 Kinase Catalytic Domain Complexed with ATP-Competitive Inhibitors: Foundations for Understanding Inhibitor Selectivity.

RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2

CARD-CONTAINING INTERLEUKIN-1 BETA-CONVERTING ENZYME-ASSOCIATED KINASE, CARD-CONTAINING IL-1 BETA ICE-KINASE, RIP-LIKE-INTERACTING CLARP KINASE, RECEPTOR-INTERACTING PROTEIN 2, RIP-2, TYROSINE-PROTEIN KINASE RIPK2, RECEPTOR-INTERACTING SERINE THREONINE- PROTEIN KINASE 2

28% PEG400, 5% GLYCEROL, 0.1M HEPES PH7.5, 0.2M CACL2

RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP

RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB -203580

RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE

RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA

RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE

HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS.

RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2 (E.C.2.7.11.1)

TRANSFERASE, KINASE DOMAIN, KINASE INHIBITOR, STRUCTURE-BASED DRUG DESIGN, INHIBITOR SELECTIVITY